Transparency bill review
June 19, 2013
A SENATE Committee review of
the Therapeutic Goods Amendment
(Pharmaceutical Transparency)
Bill 2013 has recommended that
it not be passed, because it would
“significantly curtail legitimate
interactions between therapeutic
product suppliers and healthcare
professionals”.
The private Bill was introduced
by Senator Richard Di Natale, with
the aim of restricting interactions
between pharmaceutical
companies and doctors to minimise
the opportunity to provide
inducements and “unduly influence
prescribing behaviours”.
Key proposed provisions included
banning payment for doctors to
travel or attend education seminars
and scientific conferences, banning
the sponsorship of educational
meetings overseas, and “limiting
gifts and lavish hospitality”.
It was referred to the committee
in March this year, and after
receiving evidence and a series of
submissions the outcome has been
a recommendation not to proceed.
The committee’s report, released
yesterday, has concluded that “it is
appropriate that the relationship
between medical practitioners
and pharmaceutical companies be
regulated through industry codes”.
The report also notes that some
aspects of the Bill are weaker
than the existing Medicines
Australia code of conduct, with the
committee formally recommending
that the Bill not be passed.
The above article was sent to subscribers in Pharmacy Daily's issue from 19 Jun 13To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 19 Jun 13
Warning: Undefined variable $flipbook_id in
/home/pharmacydaily.com.au/public_html/wp-content/themes/child-custom-theme/functions.php on line
1259
Warning: Undefined variable $o_shortcode_atts in
/home/pharmacydaily.com.au/public_html/wp-content/themes/child-custom-theme/functions.php on line
1263
Warning: Undefined variable $output in
/home/pharmacydaily.com.au/public_html/wp-content/themes/child-custom-theme/functions.php on line
1266
